Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.43 |
| ▸ | GPR6 | P46095 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979786 | 0.80 | CD274 (0.55) | NPC1RAB9AP2RX7CD274KDM4E | |
| SCHEMBL27965599 | 0.80 | NPC1 (0.56) | NPC1RAB9AP2RX7MAPTGAA | |
| SCHEMBL29144135 | 0.77 | NPC1 (0.47) | NPC1RAB9AMAPTNFKB1NFKB2 | |
| SCHEMBL30082269 | 0.76 | P2RX7 (0.50) | NPC1RAB9AP2RX7GRM4GPR6 | |
| SCHEMBL29050804 | 0.76 | P2RX7 (0.50) | NPC1RAB9AP2RX7GRM4GPR6 | |
| SCHEMBL28194414 | 0.75 | P2RX7 (0.57) | RAB9AP2RX7MAPTGRM4MEN1 | |
| SCHEMBL9901399 | 0.75 | MCL1 (0.66) | NPC1RAB9AP2RX7GAAGRM4 | |
| SCHEMBL30763135 | 0.75 | MCL1 (0.66) | NPC1RAB9AP2RX7GAAGRM4 | |
| SCHEMBL21412229 | 0.75 | PDCD1 (0.58) | NPC1RAB9ACD274 | |
| SCHEMBL20539477 | 0.75 | PDCD1 (0.49) | NPC1RAB9AMAPTNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533354-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-114340633-A | Triaryl compounds for the treatment of PD-L1 disease | 凯莫森特里克斯股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3968996-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200383979-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2020-12-10 | — | — | US | disclosed |
| WO-2020232256-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020232256-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533354-B2 | Triaryl compounds for treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | NPC1 1076/4885RAB9A 1006/4885P2RX7 2250/4885 |
| US-20200383979-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | NPC1 1417/4885RAB9A 364/4885P2RX7 1744/4885 |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | NPC1 1417/4885RAB9A 364/4885P2RX7 1744/4885 |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CD274, PDCD1, PDCD1LG2 | NPC1 1417/4885RAB9A 364/4885P2RX7 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.